First Tracks Biotherapeutics Stock

First Tracks Biotherapeutics P/CF

The P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics (TRAX) as of Aug 10, 2026 is -4.25. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -4.83 — a change of -11.98% (higher).

P/CF

-4.25

YoY

-11.98%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics is 2026 -4.25 . P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics was 2025 -4.83 . It decreases by -11.98% higher compared to the previous year.
Access this data via the Eulerpool API

First Tracks Biotherapeutics Stock analysis

What does First Tracks Biotherapeutics do? First Tracks Biotherapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about First Tracks Biotherapeutics stock

P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics is -4.25 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics changed from -4.83 to -4.25, representing a -11.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) First Tracks Biotherapeutics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s First Tracks Biotherapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — First Tracks Biotherapeutics

All Key Metrics — First Tracks Biotherapeutics